2026 ICD-10-CM Diagnosis Code C76.0Malignant neoplasm of head, face and neck
ICD-10-CM Codes›C00–D49›C76-C80›C76
- Billable — Valid for Submission
- Risk Adjusts — HCC 23
- Chronic Condition
C76.0 is a billable ICD-10-CM diagnosis code for malignant neoplasm of head, face and neck. It is valid on HIPAA claims for fiscal year 2026 (October 1, 2025 through September 30, 2026) and groups to MS-DRG 11 through 13, 146 through 148. In AHRQ's Clinical Classifications Software (CCSR), this diagnosis falls under Head and neck cancers - all other types.
For Medicare Advantage risk adjustment, C76.0 maps to CMS-HCC Category 23 (Prostate, Breast, and Other Cancers and Tumors) under the V28 model, adding a risk factor of about 0.186 for a community, non-dual, aged beneficiary in payment year 2026.
Code Identity
Code Classification
Medicare Risk Adjustment (HCC)Billing
C76.0 maps to a payment category in the CMS-HCC model used to risk-adjust Medicare Advantage payments. Weights are the published community factors for payment year 2026.
Source: CMS Payment Year 2026 risk adjustment mappings and model software. Weights are relative factors, not dollar amounts; a beneficiary's total RAF also includes demographics and interactions. Browse all CMS-HCC categories.
Approximate SynonymsGuidance
Alternate terms and clinical phrases that map to this code.
- Adenocarcinoma of head
- Adenocarcinoma of head and/or neck
- Adenocarcinoma of neck
- Carcinoma of cheek
- Carcinoma of face
- Carcinoma of nose
- Malignant melanoma of head and neck
- Malignant melanoma of neck
- Malignant neoplasm of ear, nose, and/or throat
- Malignant neoplasm of face
- Malignant neoplasm of head and/or neck
- Malignant neoplasm of neck
- Neoplasm of supraclavicular region
- Odontogenic ghost cell carcinoma
- Primary adenocarcinoma of neck
- Primary malignant neoplasm of cheek
- Primary malignant neoplasm of ear, nose AND/OR throat
- Primary malignant neoplasm of face
- Primary malignant neoplasm of head
- Primary malignant neoplasm of neck
- Primary malignant neoplasm of nose
- Primary malignant neoplasm of supraclavicular region
- Sarcoma of head and/or neck
- Squamous cell carcinoma of head and/or neck
- Squamous cell carcinoma of nose
Tabular List NotesGuidance
Coding notes and annotation back-references applicable to this code.
Inclusion Terms
- Malignant neoplasm of cheek NOS
- Malignant neoplasm of nose NOS
These terms are the conditions for which that code is to be used. The terms may be synonyms of the code title, or, in the case of "other specified" codes, the terms are a list of the various conditions assigned to that code. The inclusion terms are not necessarily exhaustive. Additional terms found only in the Alphabetic Index may also be assigned to a code.
Clinical ClassificationClinical
AHRQ’s CCSR groups this code into broader clinical categories.
Table of NeoplasmsClinical
Anatomical sites in the Table of Neoplasms that reference this code family.
| Site | Malig. Primary | Malig. Secondary | Ca in situ | Benign | Uncertain | Unspec. |
|---|---|---|---|---|---|---|
| cervical region | C76.0 | C79.89 | D09.8 | D36.7 | D48.7 | D49.89 |
| cheek | C76.0 | C79.89 | D09.8 | D36.7 | D48.7 | D49.89 |
| face NEC | C76.0 | C79.89 | D04.39 | D36.7 | D48.7 | D49.89 |
| head NEC | C76.0 | C79.89 | D04.4 | D36.7 | D48.7 | D49.89 |
| jaw | C76.0 | C79.89 | D09.8 | D36.7 | D48.7 | D49.89 |
| jaw › carcinoma (any type) (lower) (upper) | C76.0 | C79.89 | – | – | – | – |
| neck NEC | C76.0 | C79.89 | D09.8 | D36.7 | D48.7 | D49.89 |
| nose, nasal | C76.0 | C79.89 | D09.8 | D36.7 | D48.7 | D49.89 |
| parasagittal (region) | C76.0 | C79.89 | D09.8 | D36.7 | D48.7 | D49.89 |
| peritonsillar (tissue) | C76.0 | C79.89 | D09.8 | D36.7 | D48.7 | D49.89 |
| retro-orbital | C76.0 | C79.89 | D09.8 | D36.7 | D48.7 | D49.89 |
| submental | C76.0 | C79.89 | D09.8 | D36.7 | D48.7 | D49.89 |
| supraclavicular region | C76.0 | C79.89 | D09.8 | D36.7 | D48.7 | D49.89 |
| temporal › region | C76.0 | C79.89 | D09.8 | D36.7 | D48.7 | D49.89 |
Patient EducationClinical
Head and Neck Cancer
Head and neck cancer is the name for cancers that develop in the mouth, nose and sinuses, salivary glands, and throat and voice box (larynx). Most head and neck cancers are squamous cell cancers. They begin in the moist tissues that line the head and neck. The cancer cells may spread into deeper tissue as the cancer grows.
The full article covers:
- What is head and neck cancer?
- Who is more likely to develop head and neck cancer?
- What are the symptoms of head and neck cancer?
- How is head and neck cancer diagnosed?
- What are the treatments for head and neck cancer?
- Can head and neck cancer be prevented?
Read the full article at MedlinePlus
Courtesy of MedlinePlus, a service of the U.S. National Library of Medicine.
Convert C76.0 to ICD-9-CMHistory
The closest ICD-9-CM equivalents under the General Equivalence Mappings.
Code HistoryHistory
Questions About C76.0Overview
What is the ICD-10 code for malignant neoplasm of head, face and neck?
The ICD-10-CM code for malignant neoplasm of head, face and neck is C76.0 (sometimes written as C760). It is billable on HIPAA-covered claims from October 1, 2025 through September 30, 2026.
Is C76.0 (Malignant neoplasm of other and ill-defined sites) a billable code?
Yes. This is a billable ICD-10-CM code, specific enough to report malignant neoplasm of head, face and neck on HIPAA-covered claims from October 1, 2025 through September 30, 2026.
What MS-DRG does C76.0 group to?
When malignant neoplasm of head, face and neck is the principal diagnosis on an inpatient stay, it groups to MS-DRG 11, 12, 13, 146, 147, 148, with relative weights from 0.7971 to 5.4541 depending on complications. Higher weights mean higher Medicare reimbursement.
What is the ICD-9 equivalent of C76.0?
Under the General Equivalence Mappings, malignant neoplasm of head, face and neck converts to ICD-9-CM 195.0 (mal neo head/face/neck). The mapping is a direct match.
What HCC is C76.0?
C76.0 (malignant neoplasm of head, face and neck) maps to CMS-HCC Category 23 (Prostate, Breast, and Other Cancers and Tumors), commonly written as HCC 23, in the CMS-HCC V28 model used for Medicare Advantage risk adjustment in payment year 2026. It mapped to HCC 12 under the retired V24 model. It also maps in the PACE (CMS-HCC V22), ESRD (V21), and ESRD (V24) models. In the Part D prescription drug model it maps to RxHCC 22.
Does C76.0 risk-adjust for Medicare Advantage payment?
Yes. When documented and reported on a Medicare Advantage encounter, C76.0 adds a risk adjustment factor of about 0.186 to the beneficiary's RAF score for a community, non-dual, aged enrollee (published V28 weights range from 0.186 to 0.237 depending on the payment segment). A more severe related category (HCC 17, HCC 18, HCC 19, HCC 20, HCC 21, and HCC 22) supersedes it when both are reported. See the full factor table on the HCC 23 category page.
